Literature DB >> 14997029

Antiphospholipid syndrome infectious origin.

M Blank1, R A Asherson, R Cervera, Y Shoenfeld.   

Abstract

Antiphospholipid syndrome (APS) is characterized by the presence of pathogenic autoantibodies against beta 2-glycoprotein-I (beta 2GPI). The factors causing production of anti-beta 2GPI remain unidentified, but an association with infectious agents has been reported. Studies on experimental APS models proved that molecular mimicry between beta 2GPI-related synthetic peptides and structures within bacteria, viruses, tetanus toxoid, and CMV are a cause for experimental APS. Any explanation of how microbial infections might set off APS must take into account the observation that all individuals appear to harbor potentially autoreactive lymphocytes, as well as natural antiphospholipid antibodies, but that these cells or antibodies remain innocuous unless somehow activated. Herein, we discuss the association of antiphospholipid antibodies in the infectious state, molecular mimicry as a proposed cause for development of APS, and the contribution of the database to this topic.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14997029     DOI: 10.1023/B:JOCI.0000018058.28764.ce

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.542


  104 in total

1.  Catastrophic antiphospholipid syndrome associated with typhoid fever: comment on the article by Hayem et al.

Authors:  Imad Uthman; Ali Taher; Ismail Khalil; Abdul-Rahman Bizri; Azzudin E Gharavi
Journal:  Arthritis Rheum       Date:  2002-03

2.  Characteristics and pathogenic role of anti-beta2-glycoprotein I single-chain Fv domains: induction of experimental antiphospholipid syndrome.

Authors:  M Blank; A Waisman; E Mozes; T Koike; Y Shoenfeld
Journal:  Int Immunol       Date:  1999-12       Impact factor: 4.823

3.  Catastrophic antiphospholipid syndrome: clinical description and triggering factors in 8 patients.

Authors:  J Rojas-Rodriguez; M Garcia-Carrasco; M Ramos-Casals; G Enriquez-Coronel; C Colchero; R Cervera; J Font
Journal:  J Rheumatol       Date:  2000-01       Impact factor: 4.666

4.  Adhesion mechanism of human beta(2)-glycoprotein I to phospholipids based on its crystal structure.

Authors:  B Bouma; P G de Groot; J M van den Elsen; R B Ravelli; A Schouten; M J Simmelink; R H Derksen; J Kroon; P Gros
Journal:  EMBO J       Date:  1999-10-01       Impact factor: 11.598

5.  Induction of antiphospholipid antibodies by immunization with synthetic viral and bacterial peptides.

Authors:  E E Gharavi; H Chaimovich; E Cucurull; C M Celli; H Tang; W A Wilson; A E Gharavi
Journal:  Lupus       Date:  1999       Impact factor: 2.911

6.  Epitope specificity of monoclonal anti-beta 2-glycoprotein I antibodies derived from patients with the antiphospholipid syndrome.

Authors:  M X Wang; D A Kandiah; K Ichikawa; M Khamashta; G Hughes; T Koike; R Roubey; S A Krilis
Journal:  J Immunol       Date:  1995-08-01       Impact factor: 5.422

7.  Anti-cardiolipin and anti-beta2-glycoprotein I antibodies in patients with inflammatory bowel disease.

Authors:  I E Koutroubakis; E Petinaki; E Anagnostopoulou; H Kritikos; I A Mouzas; E A Kouroumalis; O N Manousos
Journal:  Dig Dis Sci       Date:  1998-11       Impact factor: 3.199

8.  A viral peptide with limited homology to a self peptide can induce clinical signs of experimental autoimmune encephalomyelitis.

Authors:  A M Gautam; R Liblau; G Chelvanayagam; L Steinman; T Boston
Journal:  J Immunol       Date:  1998-07-01       Impact factor: 5.422

9.  Immunization with anticardiolipin cofactor (beta-2-glycoprotein I) induces experimental antiphospholipid syndrome in naive mice.

Authors:  M Blank; D Faden; A Tincani; J Kopolovic; I Goldberg; B Gilburd; F Allegri; G Balestrieri; G Valesini; Y Shoenfeld
Journal:  J Autoimmun       Date:  1994-08       Impact factor: 7.094

10.  Beta 2-glycoprotein I in thrombosis: evidence for a role as a natural anticoagulant.

Authors:  T A Brighton; P J Hogg; Y P Dai; B H Murray; B H Chong; C N Chesterman
Journal:  Br J Haematol       Date:  1996-04       Impact factor: 6.998

View more
  28 in total

Review 1.  Infectious origin of the antiphospholipid syndrome.

Authors:  Y Shoenfeld; M Blank; R Cervera; J Font; E Raschi; P-L Meroni
Journal:  Ann Rheum Dis       Date:  2006-01       Impact factor: 19.103

Review 2.  Do antiphospholipid antibodies develop for a purpose?

Authors:  Joan T Merrill
Journal:  Curr Rheumatol Rep       Date:  2006-04       Impact factor: 4.592

Review 3.  Intravenous immunoglobulin therapy in antiphospholipid syndrome.

Authors:  Emiliana Konova
Journal:  Clin Rev Allergy Immunol       Date:  2005-12       Impact factor: 8.667

4.  Don't run before you can walk.

Authors:  Licia Rivoltini; Andrea Marrari; Chiara Castelli; Sergio Villa; Riccardo Valdagni
Journal:  Nat Rev Urol       Date:  2012-09-25       Impact factor: 14.432

5.  Vascular Pathophysiology in Hearing Disorders.

Authors:  Dennis R Trune; Anh Nguyen-Huynh
Journal:  Semin Hear       Date:  2012-08

Review 6.  What is antiphospholipid syndrome?

Authors:  Doruk Erkan; Michael D Lockshin
Journal:  Curr Rheumatol Rep       Date:  2004-12       Impact factor: 4.592

7.  Antiphospholipid syndrome plus rheumatic fever: a higher risk factor for stroke?

Authors:  Elisa Watanabe Camargo; Paula Vieira Freire; Clovis Artur Silva; Nelita Rocha dos Santos; Licia Maria Henrique da Mota; Rosa Maria Rodrigues Pereira; Jozélio Freire de Carvalho
Journal:  Rheumatol Int       Date:  2011-03-25       Impact factor: 2.631

8.  Incidental discovery of high systemic lupus erythematosus disease activity associated with cytomegalovirus viral activity.

Authors:  Ben Yu-Jih Su; Cheng-Yu Su; Shan-Fu Yu; Chung-Jen Chen
Journal:  Med Microbiol Immunol       Date:  2007-02-23       Impact factor: 3.402

Review 9.  Annexin A2: biology and relevance to the antiphospholipid syndrome.

Authors:  E Cockrell; R G Espinola; K R McCrae
Journal:  Lupus       Date:  2008-10       Impact factor: 2.911

Review 10.  Pathophysiology of the cochlear intrastrial fluid-blood barrier (review).

Authors:  Xiaorui Shi
Journal:  Hear Res       Date:  2016-01-20       Impact factor: 3.208

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.